We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-5.41%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$7.1B
AUM Growth
-$1.16B
Cap. Flow
-$291M
Cap. Flow %
-4.1%
Top 10 Hldgs %
41.94%
Holding
104
New
17
Increased
24
Reduced
34
Closed
18

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$151M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$136M
3
MDT icon
Medtronic
MDT
+$115M
4
DXCM icon
DexCom
DXCM
+$83.5M
5
LIVN icon
LivaNova
LIVN
+$79.9M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$149M
2
GILD icon
Gilead Sciences
GILD
+$133M
3
ONEM
1Life Healthcare
ONEM
+$129M
4
BEAM icon
Beam Therapeutics
BEAM
+$119M
5
SNY icon
Sanofi
SNY
+$96.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.86%
2 Financials 0.83%
3 Consumer Staples 0.3%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
76
Cabaletta Bio
CABA
$573M
$7.73M 0.11%
696,378
-681,941
-49% -$8.33M
XERS icon
77
Xeris Biopharma Holdings
XERS
$1.57B
$7.72M 0.11%
1,712,304
-685,137
-29% -$3.7M
AYLA
78
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$7.29M 0.1%
667,816
– –
STIM icon
79
Neuronetics
STIM
$226M
$6.18M 0.09%
+500,000
New +$7.66M
TLIS
80
DELISTED
Talis Biomedical Corporation Common Stock
TLIS
$5.14M 0.07%
+26,667
New +$6.65M
APRE icon
81
Aprea Therapeutics
APRE
$10.8M
$3.54M 0.05%
34,746
-28,690
-45% -$3.35M
SYRS
82
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.59M 0.02%
21,229
– –
OVID icon
83
Ovid Therapeutics
OVID
$572M
$490K 0.01%
121,950
– –
WVE icon
84
Wave Life Sciences
WVE
$1.02B
$443K 0.01%
79,018
– –
TCDA
85
DELISTED
Tricida, Inc. Common Stock
TCDA
$290K ﹤0.01%
54,758
-396,619
-88% -$2.49M
CSLT
86
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$15K ﹤0.01%
10,229
– –
ABBV icon
87
AbbVie
ABBV
$456B
– –
-1,388,904
Closed -$149M
ABCL icon
88
AbCellera Biologics
ABCL
$4.02B
– –
-500,000
Closed -$20.1M
BNTX icon
89
BioNTech
BNTX
$28B
– –
-580,746
Closed -$47.3M
CNC icon
90
Centene
CNC
$32.3B
– –
-554,962
Closed -$33.3M
GILD icon
91
Gilead Sciences
GILD
$185B
– –
-2,288,846
Closed -$133M
LUNG icon
92
Pulmonx
LUNG
$104M
– –
-275,000
Closed -$19M
MASS icon
93
908 Devices
MASS
$459M
– –
-75,000
Closed -$4.27M
OM icon
94
Outset Medical
OM
$76.9M
– –
-4,667
Closed -$3.98M
RIGL icon
95
Rigel Pharmaceuticals
RIGL
$875M
– –
-74,458
Closed -$2.61M
SEER icon
96
Seer Inc
SEER
$111M
– –
-125,000
Closed -$7.02M
SNY icon
97
Sanofi
SNY
$107B
– –
-1,984,690
Closed -$96.4M
UBER icon
98
Uber
UBER
$157B
– –
-833,845
Closed -$42.5M
VAPO
99
DELISTED
Vapotherm, Inc. Common Stock
VAPO
– –
-3,125
Closed -$672K
EAR
100
DELISTED
Eargo, Inc. Common Stock
EAR
– –
-6,474
Closed -$5.8M
1 2 3
4
5

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2021 Portfolio in Review

As of Q1 2021, Redmile Group held 104 positions worth $7.1B, down 14% from $8.26B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Redmile Group withdrew a net $291M in Q1 2021, closing 18 positions and reducing 34 holdings. Its most notable exit was AbbVie, an estimated $149M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Redmile Group opened a new position in Seagen Inc. Common Stock worth $130M.

  • Redmile Group's largest Q1 2021 buy was Seagen Inc. Common Stock: 937,045 shares worth $130M.
  • Redmile Group added most to Fate Therapeutics in Q1 2021, an estimated $31.4M increase.
  • Redmile Group's biggest Q1 2021 reduction was 1Life Healthcare, cutting an estimated $129M.
  • Redmile Group fully exited AbbVie in Q1 2021, selling an estimated $149M.
  • Redmile Group's ten largest holdings make up 42% of its $7.1B portfolio in Q1 2021.
  • Redmile Group opened 17 new positions and closed 18 in Q1 2021.
  • Redmile Group's portfolio value fell 14% quarter-over-quarter to $7.1B.

Based on Redmile Group's 13F filing for Q1 2021, filed 17 May 2021.